PDRN in Skincare: Injectable Evidence vs. What a Cream Can Do

PDRN has moved from clinic menus to cream and serum labels, and the question behind most searches is simple: does the version in a jar do what the version in a syringe is studied for? The published record is thinner than the marketing, and one number from skin-penetration research explains why.

What PDRN is

PDRN stands for polydeoxyribonucleotide. In the pharmaceutical literature it is a mixture of DNA fragments with molecular weights between 50 and 1,500 kDa, produced by purifying and sterilizing DNA from salmon trout or chum salmon sperm, a process meant to remove proteins and peptides that could provoke immune reactions. Cosmetic labels often list it as sodium DNA, salmon DNA, or simply PDRN. Related materials called polynucleotides (PN) are similar in spirit and often discussed together.

The proposed mechanism is the part that excites researchers. Laboratory and animal work suggests PDRN engages adenosine A2A receptors and also supplies nucleosides and nucleotides to the cell's 'salvage pathway,' which recycles building blocks. That is a plausible story for how a material could support skin repair. A plausible story is not the same as a result on a person's face, and the review that lays it out is mainly about a registered drug, not a cosmetic cream.

What the human studies cover

The most useful recent summary is a 2025 systematic review in the Journal of Cosmetic Dermatology. It searched Embase, Medline and Cochrane for studies published between 2010 and early 2024 and ended up with nine studies, of low and moderate quality, covering 219 patients. The studies varied in injection areas and techniques. The authors reported promising outcomes for the look of lines, texture and elasticity, with statistically significant results in several studies, mild and transient side effects, and moderate to high patient satisfaction, while stating that consensus on optimal use is limited and that rigorous high-quality studies are needed.

Read that carefully. The word 'injections' is doing the work. These are procedures performed by clinicians, not creams spread on skin at home. Nine low-to-moderate quality studies and 219 people is a start, and a review author who says more rigorous work is needed is telling you where the ceiling is.

The size problem for creams

Skin's outer layer is a barrier, and size matters. A widely cited 2000 analysis in Experimental Dermatology argued that a compound generally needs a molecular weight under 500 daltons to be absorbed through the skin. The authors' reasoning: virtually all common contact allergens fall under 500 daltons, common topical drugs sit under that mark, and every known transdermal delivery drug does too.

Now compare. 500 daltons is 0.5 kDa. PDRN as described in the pharmaceutical review spans 50 to 1,500 kDa, which is roughly 100 to 3,000 times the rule's ceiling. The 500 dalton rule is a rule of thumb, not a physical law, and formulators use delivery tricks and smaller fragments to try to get around it. But it is a fair reason to be skeptical that a large DNA fragment applied to intact skin reaches living layers in meaningful amounts. Anything that stays on the surface may still act as a humectant or a film-former, which can make skin feel smoother and look more hydrated, but that is a different claim from tissue repair.

What a cream label can and cannot tell you

• 'PDRN' or 'sodium DNA' high in the ingredient list tells you the material is present, not what percentage and not what molecular weight. Many cosmetic versions use shorter, hydrolyzed fragments, which changes the comparison to the injectable literature entirely.
• 'Clinically tested' language often points to a small in-house panel measuring hydration or smoothness. Check whether the test was on the finished cream, how many people took part, and whether a vehicle-only comparison was included.
• Studies cited on the product page may be injectable or drug studies, like the ones above. That is evidence for another product, not this one.
• Price as a signal: a premium price reflects marketing and sourcing costs, not proof of performance.

If you want to try one anyway

A reasonable, low-risk approach, built from general sensitivity precautions rather than any PDRN trial:

1. Patch test on the inner forearm for three days before putting it on your face, especially if you have fish or seafood allergies, since the source material is salmon-derived. If you are allergic, ask your doctor before using it.
2. Introduce it alone for two weeks so any redness or stinging can be traced to it.
3. Keep the rest of your routine boring: a gentle cleanser, a moisturizer you already tolerate, and broad-spectrum sunscreen each morning.
4. Judge by what you can see and feel at 8 to 12 weeks, such as smoother texture and a more even look, and photograph your skin in the same light so you are not relying on memory.
5. If you are pregnant or breastfeeding, talk to your doctor about new products first.

Where the evidence is headed

Better trials would compare a defined PDRN cream against a matched vehicle cream, state the fragment size and concentration, and measure outcomes with instruments, not just self-reported satisfaction. The pieces that exist today, a registered-drug review, a small low-to-moderate quality injectable literature, and a penetration rule that argues against large molecules crossing the barrier, do not add up to proof for topical PDRN. They add up to an interesting ingredient with a mechanism worth studying.

The takeaway

PDRN has real research behind it, but that research is about injections and a pharmaceutical form, not the serums on shelves. Because the ingredient's reported size is far above the 500 dalton absorption guideline, approach claims of deep repair from a cream with caution. If you like the way a PDRN product feels and your skin looks calm and smooth with it, that is a fine reason to keep using it. Just do not pay extra on the assumption that injectable results travel to the jar.